Biomaterial Database

Fibrinolytic activity of immobilized plasminogen activator. 1985

F F Senatore, and F R Bernath

Urokinase (UK) was immobilized onto the inner surface of 4-mm ID canine autogenous fibrocollagenous tubes in order to develop a fibrinolytic small-caliber vascular prosthesis. Using a glutaraldehyde entrapment process, the immobilized urokinase was compared to its soluble counterpart for its ability to degrade fibrin. Fibrin Degradation Product (FDP) levels increased with time for both soluble and immobilized urokinase, where FDP levels at complete lysis for both soluble and immobilized urokinase, where FDP levels at complete lysis were measured at 165.83 +/- 6.44 micrograms/ml. The rate of fibrinolysis was slower for the immobilized urokinase compared to its soluble form. The inhibitory effect of alpha-2 plasmin inhibitor was shown to be inimical to urokinase activity. Using a differential recirculation reactor apparatus and an esterolytic reaction involving N-alpha-acetyl-L-lysine methyl ester HCl, the amount of urokinase immobilized onto fibrocollagenous tubes (FCT) was measured to be 110 +/- 14 CTA units of UK per millimeter graft. The stability of immobilized urokinase was maintained for at least 75 hours of operation time, which corresponds to 1 year maintained for at least 75 hours of operation time, which corresponds to 1 year of storage time. Urokinase-bound fibrocollagenous tubes (UK-FCT), in addition to control FCT's, Perloff prostheses, and the autogenous saphenous vein, were interposed onto the carotid artery of canine mongrels using end-to-end anastomoses with 7-0 prolene sutures. Results indicate that the patency rates for UK-FCT's were 86% and 62% after 1 and 2 months, respectively. The Perloff graft and the control FCT had much lower patency rates. These results indicate that immobilizing urokinase is a viable method of producing a small-caliber biocompatible vascular prosthesis.

UI	MeSH Term	Description	Entries
D001807	Blood Vessel Prosthesis	Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels.	Vascular Prosthesis,Blood Vessel Prostheses,Tissue-Engineered Vascular Graft,Graft, Tissue-Engineered Vascular,Grafts, Tissue-Engineered Vascular,Prostheses, Blood Vessel,Prostheses, Vascular,Prosthesis, Blood Vessel,Prosthesis, Vascular,Tissue Engineered Vascular Graft,Tissue-Engineered Vascular Grafts,Vascular Graft, Tissue-Engineered,Vascular Grafts, Tissue-Engineered,Vascular Prostheses,Vessel Prostheses, Blood,Vessel Prosthesis, Blood
D004285	Dogs	The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)	Canis familiaris,Dog
D004800	Enzymes, Immobilized	Enzymes which are immobilized on or in a variety of water-soluble or water-insoluble matrices with little or no loss of their catalytic activity. Since they can be reused continuously, immobilized enzymes have found wide application in the industrial, medical and research fields.	Immobilized Enzymes,Enzyme, Immobilized,Immobilized Enzyme
D005338	Fibrin Fibrinogen Degradation Products	Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.	Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005343	Fibrinolytic Agents	Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.	Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D000979	alpha-2-Antiplasmin	A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin.	alpha 2-Plasmin Inhibitor,Serpin F2,alpha(2)-Plasmin Inhibitor,alpha-2 Antiplasmin,alpha 2 Antiplasmin,alpha 2 Plasmin Inhibitor
D014568	Urokinase-Type Plasminogen Activator	A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES.	Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator